Outpatient vs. inpatient liso-cel treatment for R/R LBCL at community sites
Sidana S, Patel KK, Peres LC, et al. Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. Blood. 2024; (doi: 10.1182/blood.2024025945).Linhares Y, Freytes CO, Cherry M, et al. OUTREACH: Phase 2 Study of Lisocabtagene Maraleucel as Outpatient or Inpatient Treatment at Community Sites for R/R LBCL. Blood Advances. 2024; (doi: 10.1182/bloodadvances.2024013254).
Based on results from the OUTREACH study, outpatient monitoring appears to be both safe and effective for patients with relapsed/refractory large B-cell lymphoma who undergo lisocabtagene maraleucel (liso-cel) infusion at community sites. The Phase II investigation included 82 adults who received the autologous chimeric antigen receptor T-cell treatment after trying two or more previous lines of therapy. Participants were followed for a median of 10.6 months, with 30% had inpatient monitoring and 70% monitored on an outpatient basis. Safety was the primary outcome, and no patients in either group developed grade >3 cytokine release syndrome. Neurological events, prolonged cytopenia, and infections occurred in 12%, 33%, and 12% of outpatients, respectively, compared with 4%, 32%, and 8% of inpatients. The data also revealed 25% of outpatients did not require hospitalization at all after infusion and those who did had shorter median initial stays than inpatients, at 6 days versus 15 days. Objective response rates and complete response rates were 80% and 54%, with a median duration of response of 14.75 months. Collectively, the findings associate outpatient monitoring after liso-cel with robust, durable treatment response and favorable le safety.